Trial record 3 of 50 for:    Obsessive Compulsive Disorder [CONDITION] AND NIH [SPONSOR-COLLABORATORS-CLASS] NOT NIMH [ORGANIZATION-NAME]

I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers

This study has been completed.
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00001771
First received: November 3, 1999
Last updated: March 3, 2008
Last verified: May 2003
  Purpose

Abnormalities in the re-uptake of dopamine and serotonin have been described in various neuropsychiatric disorders and substance abuse. [I-123] Beta-CIT is a recently developed radioligand for SPECT imaging of dopamine and serotonin transporters. [I-123]Beta-CIT SPECT has been used at the SPECT-lab of the Clinical Brain Disorders Branch in over fifty subjects without adverse events. Due to the trace concentrations used, a pharmacological effect of Beta-CIT is unlikely and has not been observed. The purpose of this study is to use Beta-CIT and SPECT to study the expression of dopamine and serotonin transporters in vivo in normal controls and various patient populations to address hypothesized abnormalities of the transporters in different disorders and to understand the effects of genetic variations in the genes of these transporters on their in vivo expression.


Condition
Healthy
Mental Disorder
Obsessive Compulsive Disorder
Schizophrenia
Tourette Syndrome

Study Type: Observational
Official Title: I-123 Beta-CIT SPECT Studies of Dopamine and Serotonin Transporters in Neuropsychiatric Patients and Normal Volunteers

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 112
Study Start Date: May 1998
Estimated Study Completion Date: May 2003
Detailed Description:

Abnormalities in the re-uptake of dopamine and serotonin have been described in various neuropsychiatric disorders and substance abuse. [I-123] Beta-CIT is a recently developed radioligand for SPECT imaging of dopamine and serotonin transporters. [I-123]Beta-CIT SPECT has been used at the SPECT-Lab of the Clinical Brain Disorders Branch in over fifty subjects without adverse events. Due to the trace concentrations used, a pharmacological effect of Beta-CIT is unlikely and has not been observed. The purpose of this study is to use Beta-CIT and SPECT to study the expression of dopamine and serotonin transporters in vivo in normal controls and various patient populations to address hypothesized abnormalities of the transporters in different disorders and to understand the effects of genetic variations in the genes of these transporters on their in vivo expression.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

INCLUSION CRITERIA:

No Axis I or Axis II diagnoses.

EXCLUSION CRITERIA FOR ALL SUBJECTS:

If the pregnancy test is positive or if the woman has reason to believe she might be pregnant, she will be excluded from this study.

Women who are breastfeeding will be excluded from this study to avoid unwarranted risk to their children.

Subjects with a prior reaction to iodine, iodine compounds, or shellfish will be excluded from this study.

Subjects with a history of thyroid disease or dysfunction will be excluded from this study.

Subjects with a history of recent substance abuse will be excluded from this study.

Subjects with metal objects in their bodies as specified in our MRI protocol (91-M-0124) will be excluded from this study.

If a structural abnormality of the brain is detected on MRI, subjects will be excluded from the study.

EXCLUSION CRITERIA FOR NORMAL CONTROLS:

Subjects with an Axis I or Axis II disorder will be excluded.

Subjects with concomitant medical or neurological disorders which require ongoing medication, or which may affect the central nervous system will be excluded.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001771

Locations
United States, Maryland
National Institute of Mental Health (NIMH)
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00001771     History of Changes
Other Study ID Numbers: 980094, 98-M-0094
Study First Received: November 3, 1999
Last Updated: March 3, 2008
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Obsessive Compulsive Disorder
Receptors
Re-Uptake
Neurotransmitters
Neuroimaging
Drug Abuse
Serotonin
Brain Scan
Tourette's Syndrome
Schizophrenia
Normal Volunteer

Additional relevant MeSH terms:
Mental Disorders
Psychotic Disorders
Obsessive-Compulsive Disorder
Compulsive Personality Disorder
Schizophrenia and Disorders with Psychotic Features
Anxiety Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tic Disorders
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Mental Disorders Diagnosed in Childhood
Personality Disorders
Schizophrenia
Tourette Syndrome
Serotonin
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 28, 2014